Richwood Investment Advisors LLC Has $666,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Jul 7th, 2023

Richwood Investment Advisors LLC grew its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,295 shares of the company’s stock after acquiring an additional 85 shares during the period. Richwood Investment Advisors LLC’s holdings in Johnson & Johnson were worth $666,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Glassy Mountain Advisors Inc. bought a new position in Johnson & Johnson in the 4th quarter worth approximately $35,000. GW&K Investment Management LLC bought a new position in Johnson & Johnson in the 4th quarter worth approximately $35,000. Dark Forest Capital Management LP raised its position in Johnson & Johnson by 1,044.4% in the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after purchasing an additional 188 shares during the last quarter. Retirement Financial Solutions LLC bought a new position in Johnson & Johnson in the 4th quarter worth approximately $40,000. Finally, Ruedi Wealth Management Inc. bought a new position in Johnson & Johnson in the 4th quarter worth approximately $42,000. Institutional investors own 67.57% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the transaction, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Credit Suisse Group boosted their price objective on shares of Johnson & Johnson from $168.00 to $170.00 in a research report on Friday, May 5th. TheStreet cut shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, May 19th. Citigroup started coverage on shares of Johnson & Johnson in a research report on Tuesday, May 30th. They set a “buy” rating and a $185.00 target price for the company. Raymond James dropped their target price on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research report on Wednesday, April 19th. Finally, StockNews.com started coverage on shares of Johnson & Johnson in a research report on Thursday, May 18th. They set a “strong-buy” rating for the company. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $171.57.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $161.60 on Friday. The firm has a market cap of $419.95 billion, a PE ratio of 33.81, a PEG ratio of 2.79 and a beta of 0.55. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $181.04. The company has a fifty day moving average price of $160.72 and a 200 day moving average price of $162.73.

Johnson & Johnson (NYSE:JNJ – Free Report) last announced its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The firm had revenue of $24.75 billion during the quarter, compared to analyst estimates of $23.61 billion. During the same period in the prior year, the business earned $2.67 EPS. The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. Research analysts predict that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd were paid a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.95%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend was Monday, May 22nd. Johnson & Johnson’s dividend payout ratio is currently 99.58%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.